Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)

NCT02862457 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms
Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Epacadostat 25 mg
DRUG: Epacadostat 100 mg
BIOLOGICAL: pembrolizumab 200 mg
DRUG: Cisplatin 75 mg/m^2
DRUG: Carboplatin Area Under the Curve (AUC) 5
DRUG: Pemetrexed 500 mg/m^2
DRUG: Paclitaxel 200 mg/m^2
DRUG: Carboplatin AUC 6

Sponsor

Merck Sharp & Dohme LLC